Australia markets closed

Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
14.82-0.22 (-1.46%)
At close: 03:04PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 2.18B
Enterprise value 2.14B
Trailing P/E 149.82
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.83
Price/book (mrq)1.60
Enterprise value/revenue 4.09
Enterprise value/EBITDA 32.80

Trading information

Stock price history

Beta (5Y monthly) 0.12
52-week change 3-33.95%
S&P500 52-week change 323.76%
52-week high 338.23
52-week low 313.73
50-day moving average 317.39
200-day moving average 321.99

Share statistics

Avg vol (3-month) 31.69M
Avg vol (10-day) 31.13M
Shares outstanding 5144.79M
Implied shares outstanding 6144.79M
Float 835.38M
% held by insiders 175.05%
% held by institutions 10.67%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.25
Forward annual dividend yield 41.66%
Trailing annual dividend rate 30.25
Trailing annual dividend yield 31.66%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 429 May 2024
Last split factor 21.8:1
Last split date 317 June 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -2.14%
Operating margin (ttm)11.02%

Management effectiveness

Return on assets (ttm)-0.89%
Return on equity (ttm)-0.70%

Income statement

Revenue (ttm)523.84M
Revenue per share (ttm)3.92
Quarterly revenue growth (yoy)2.20%
Gross profit (ttm)N/A
EBITDA 8.38M
Net income avi to common (ttm)-11.23M
Diluted EPS (ttm)-0.08
Quarterly earnings growth (yoy)-11.60%

Balance sheet

Total cash (mrq)226.18M
Total cash per share (mrq)1.59
Total debt (mrq)192.95M
Total debt/equity (mrq)13.96%
Current ratio (mrq)5.48
Book value per share (mrq)9.60

Cash flow statement

Operating cash flow (ttm)28.36M
Levered free cash flow (ttm)160.4M